Shaun Chilton's AGM opening statement7 Jul 2025 08:43
I think there’ll be a lot of questions around deals, financing, etc., so I’m going to read out a brief statement. Clearly, there will be time for questions, but it might make things more efficient.
As Chris will outline in her presentation, and as published in this morning’s RNS, Avacta is discussing FAP-Dox with a range of parties. This is both for separate indications and multiple indications.
We are also delighted to see initial signs of efficacy in both Phase 1b indications. You’re also aware we’re in discussions with the use of pre|CISION as a platform to put through other parties’ payloads.
There’s an incredible amount of interest in AVA6103, or FAP-EXd as we now call it, although the company’s strategy at this point is to protect this asset until we have sight of the initial human data, such is its value.
In respect of the bond, the Board is acutely aware of the impact the bond has on shareholder sentiment. We do not believe, though, the share price reflects the incredible progress pre|CISION has made in the clinic over the last four years.
You’re aware of the additions to our Board, management team, and broker advisors in the last few days and weeks. Attracting these individuals demonstrates the intrinsic value of pre|CISION.
Taking all of that into consideration, we remain confident the market’s attention will soon return to the excellent progress pre|CISION continues to make in the clinic.
I’d like to thank you for your attendance today. I know it was early, and I appreciate you all getting here — and also for your patience over the last year. I know the journey has not been easy, but we remain incredibly excited about the second half of 2025 and early 2026.
Sign In
Follow the stocks
